Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the captioned application:

Listing of Claims:

Claims 1-28 (cancelled)

:Claim 29 (currently amended): A solid dosage unit simethicone and an adsorbent selected from the group consisting of magnesium aluminometasilicate and silicified microcrystalline cellulose, wherein the proportionate amounts, by weight, is about 1: about 0.5 to about 0.85 : about 0.9 to about 1.30 per solid dosage unit.

Claim 30 (new): A solid dosage unit of claim 29, further comprising at least one additional active ingredient.

Claim 31 (new): A solid dosage unit of claim 30, wher ein the active agent is selected from the group consisting of bisacodyl, famotidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Claim 32 (new): A solid dosage unit of claim 21, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.

Claim 33 (new): A solid dosage united of claim 32 having at least 34 wt% simethicone.

Claim 34 (new): A solid dosage unit of claim 33 having from about 35 wt to about 54 wt% simethicone.

Claim 35 (new): A solid dosage unit of claim 29 having from about 19 wt% to about 29 wt% silicified microcrystalline cellulose and from about 31 wt% to about 39 wt% magnesium aluminometasilicate.

Claim 36 (new): A solid dosage unit of claim 35 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33 wt% to about 37 wt% magnesium aluminometasilicate.

Claim 37 (new): A solid oral dosage form of claim 29, wherein the compressed admixture is a tablet having a hardness value of at least 2 kp/cm^2.

Claim 38. (new) A solid oral dosage form of claim 37, wherein the compressed admixture is a tablet having a hardness value of from about 5 to about 10 kp/cm^2.